Associated tags: Patient, Human, Intubation, Coma, OXY, Blood, Medical device, Food, Health, Carbon, FDA, Physician
RA'ANANA, Israel, May 2, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.
Key Points:
- RA'ANANA, Israel, May 2, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.
- Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced the start of production of the INSPIRA ART100 medical device.
- The INSPIRA ART100 device is being contract manufactured by a leading technology company that provides high-technology electronic assembly solutions for the medical, aero-space and aviation, communications and defense industries.
- The manufacturer has commenced with the production and assembly of the first batch of INSPIRA ART100 devices, which will be used for deployment in several initial sites, subject to U.S. Food and Drug Administration (FDA) regulatory clearance.
Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced that it has received the Canadian Standards Association (CSA) Certification of Compliance to U.S. standards for the INSPIRA ART100 device.
Key Points:
- Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced that it has received the Canadian Standards Association (CSA) Certification of Compliance to U.S. standards for the INSPIRA ART100 device.
- This is a positive recognition of our product's quality and safety standards.
- The Certification of Compliance allows for the INSPIRA ART100 System to bear the CSA Mark; C878081 MEDICAL ELECTRICAL EQUIPMENT/SYSTEMS - Certified to U.S. Standards.
- Inspira Chief Operations Officer Mr. Avi Shabtay stated: "This certification is more than just a mark of compliance.
Retrieved on:
Wednesday, April 10, 2024
Hebrew University of Jerusalem,
Bacteria,
Physiology,
Research,
Environment,
ART,
Al-Quds,
Patient,
OXY,
Allergy,
Intensive care medicine,
Pharmaceutical industry Once developed, Inspira plans to integrate the bio-electronic novel physical stimulation technology, into the INSPIRA™ ART patient treatment.
Key Points:
- Once developed, Inspira plans to integrate the bio-electronic novel physical stimulation technology, into the INSPIRA™ ART patient treatment.
- The results of the in vitro study showed a 75% reduction in bacterial growth 4 hours after the application of the treatment and a 100% reduction within 24 hours.
- The in vitro study was carried out at the Hebrew University of Jerusalem and involved testing bioelectric patches in an in vitro environment.
- As part of the in vitro study, bacteria were cultured and spread on agar in petri dishes.
Retrieved on:
Thursday, February 8, 2024
RA'ANANA, Israel, Feb. 8, 2024 /PRNewswire/ -- Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Shamir Medical Center (Assaf Harofeh), a renowned healthcare institution in central Israel. The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical deployment strategy.
Key Points:
- The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical deployment strategy.
- The LOI solidifies the mutual commitment of both parties to assess the integration and performance of the INSPIRA™ ART100 device ("Device) within Shamir Medical Center's clinical environment.
- This includes evaluating the device's fit with the hospital's clinical needs, efficiency in workflow, and overall impact on healthcare delivery.
- The evaluation will be led by Dr. Eduard Ilgiyaev, Director of the Intensive Care Unit at Shamir Medical Center and a leading pioneer of critical care medicine in Israel.
Retrieved on:
Thursday, December 28, 2023
The aggregate gross proceeds from the offering were approximately $3.88 million, before deducting placement agent fees and other estimated offering expenses.
Key Points:
- The aggregate gross proceeds from the offering were approximately $3.88 million, before deducting placement agent fees and other estimated offering expenses.
- The securities described above (excluding the unregistered warrants and the ordinary shares underlying the unregistered warrants) were offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form F-3 (Registration No.
- The offering of such securities in the registered direct offering were made only by means of a prospectus supplement that forms a part of the registration statement.
- A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering was filed with the SEC and is available on the SEC's website located at http://www.sec.gov.
Retrieved on:
Thursday, September 28, 2023
Face,
Food and Drug Administration,
ART,
CPB,
Research,
Extracorporeal Life Support Organization,
Inspira Health Network,
ELSO,
Hospital,
Patient,
OXY,
FDA,
Health,
Conference,
Food,
Medical device,
Pharmaceutical industry RA'ANANA, Israel, Sept. 28, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce the unveiling of its INSPIRA ART line at the Extracorporeal Life Support Organization (ELSO) Conference in Seattle, WA.
Key Points:
- The ELSO conference brings together healthcare institutions, researchers, and industry partners
RA'ANANA, Israel, Sept. 28, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.
- Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce the unveiling of its INSPIRA ART line at the Extracorporeal Life Support Organization (ELSO) Conference in Seattle, WA.
- ELSO is dedicated to improving a special type of life support called extracorporeal life support, which involves using external devices to support patients with severe breathing and/or heart problems.
- Inspira will be introducing its new INSPIRA ART device line, revealing the INSPIRA ART100 device at ELSO, which marks a significant achievement by its team of experts.
Retrieved on:
Wednesday, August 9, 2023
Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce it has completed a Usability Study in Boston, Massachusetts for its INSPIRA ART100 device.
Key Points:
- Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce it has completed a Usability Study in Boston, Massachusetts for its INSPIRA ART100 device.
- The Usability Study included U.S. healthcare professionals who participated in testing and examining the INSPIRA ART100 in a setting designed to consider human factors of the intended users, uses and use environments.
- Dagi Ben Noon, Inspira Technologies' Chief Executive Officer, stated: "We are advancing with the INSPIRA ART100.
- The INSPIRA ART100 may be suitable for a wide range of extracorporeal treatments in the ICU and during heart surgery.
Carbon,
Intensive care medicine,
Perfusion,
Hospital,
Patient,
Blood,
OXY,
Regulation of tobacco by the U.S. Food and Drug Administration,
Food,
Nursing,
Pharmaceutical industry RA'ANANA, Israel, July 19, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, announced today that it has entered into a collaboration agreement with Perfusion Solution, Inc. ("Perfusion Solution"). The collaboration involves combining the INSPIRA™ ART100 product with Perfusion Solution's broad commercial footprint and infrastructure across the United States.
Key Points:
- Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, announced today that it has entered into a collaboration agreement with Perfusion Solution, Inc. ("Perfusion Solution").
- The collaboration involves combining the INSPIRA™ ART100 product with Perfusion Solution's broad commercial footprint and infrastructure across the United States.
- Mr. Joe Hayon, Inspira Technologies' president, director & co-founder stated: "This collaboration combines our INSPIRA ART100 with Perfusion Solution's diverse commercial infrastructure and outreach.
- Mr. Jon Bohannan, VP of Sales and Clinical Integration for Perfusion Solution stated: "We are honored to join in a business collaboration with Inspira Technologies.
Coma,
Carbon,
Patent,
Patient,
Physician,
Blood,
Intubation,
OXY,
Entrepreneurship,
Mortality,
FDA,
Health,
Regulation of tobacco by the U.S. Food and Drug Administration,
Food,
Medical device,
Renewable energy Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, is thrilled to present our latest investor deck (the "Investor Deck"), unveiling unparalleled opportunities that have the potential to reshape the acute respiratory care landscape introducing empowered breathing without the use of lungs.
Key Points:
- Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, is thrilled to present our latest investor deck (the "Investor Deck"), unveiling unparalleled opportunities that have the potential to reshape the acute respiratory care landscape introducing empowered breathing without the use of lungs.
- INSPIRA™ AI is embedded into the INSPIRA™ ART500 to target hyper-personalized patient care, providing empowered breathing without lungs.
- Our Investor Deck highlights our vision, achievements, our focus going forward and what we believe are remarkable opportunities.
- Key Highlights of the Investor Deck include:
Revolutionary Acute Respiratory Care Innovations: The Investor Deck showcases our cutting-edge extracorporeal blood circulation medical devices.
Hebrew University of Jerusalem,
Food and Drug Administration,
Clinical trial,
Al-Quds,
Coronavirus Scientific Advisory Board,
MBA,
Medicine,
CMO,
Strategic planning,
Doctor of Philosophy,
Inspira Health Network,
National Association Medical Staff Services,
Patient,
Master of Science,
OXY,
FDA,
Health,
Family,
Food,
Medical device,
Nursing,
Health Economics,
Molecular biology RA'ANANA, Israel, May 30, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer ("CMO"). Dr. Nir brings a wealth of expertise and a distinguished track record in the field of medicine and healthcare administration to the Company.
Key Points:
- Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer ("CMO").
- As CMO, Dr. Nir will play a critical role in overseeing and guiding Inspira's medical operations and strategic initiatives.
- On the appointment, Inspira Technologies' CEO, Dagi Ben Noon said, "We are thrilled to have Dr. Nir as our new CMO.
- Please join us in welcoming Dr. Nir to her new position in our Inspira Technologies family.
